Search
Odyssey Therapeutics Ord Shs (Proposed)
ODTXAdd to Watchlist
19.140USD
-0.960-4.78%
Close 11-13 16:00（ET）
919.87MMarket Cap
LossP/E TTM
Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to Odyssey Therapeutics Ord Shs (Proposed) in the past month.
Buy
2 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
39.000USD+99.59%
ODTX Analyst Recommendation Trends
In the current month, ODTX has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ODTX average Analyst price target in the last month is 39.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2
2
2
2
0
0
0
0
4
4
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
5
5
0
0
0
0
ODTX Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, ODTX EPS is projected to reach -1.136 in FY2026Q4, following reported EPS of -1.105 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-1.25
-1.01
-1.08
-1.14
-1.13
Actual
-0.81
-1.74
-1.10
--
--
Surprise
+35.24%
-72.28%
-2.72%
--
--
FAQs
What is Odyssey Therapeutics Ord Shs (Proposed)'s price target?
Analysts forecast that Odyssey Therapeutics Ord Shs (Proposed)'s price target is USD 36.60, with the highest forecast at USD 44.00 and the lowest forecast at USD 27.00.
How have Odyssey Therapeutics Ord Shs (Proposed)ODTX's recent earnings per share performed?
The market expectation was USD -1.10, while Odyssey Therapeutics Ord Shs (Proposed)ODTX's earnings per share (EPS) for the previous quarter was USD -1.74. EPS for the next quarter is expected at USD -1.14.
What is the analyst rating for Odyssey Therapeutics Ord Shs (Proposed)?
Based on the ratings of Odyssey Therapeutics Ord Shs (Proposed)'s stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.